Details
Stereochemistry | RACEMIC |
Molecular Formula | C32H39NO4 |
Molecular Weight | 501.6564 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN2CCC(CC2)C(O)(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=RWTNPBWLLIMQHL-UHFFFAOYSA-N
InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)
DescriptionCurator's Comment: Description was created based on several sources, including https://www.drugbank.ca/drugs/DB00950
Curator's Comment: Description was created based on several sources, including https://www.drugbank.ca/drugs/DB00950
Fexofenadine is a second-generation, long lasting H1-receptor antagonist (antihistamine) which has a selective and peripheral H1-antagonist action. Histamine is a chemical that causes many of the signs that are part of allergic reactions, such as the swelling of tissues. Histamine is released from histamine-storing cells (mast cells) and attaches to other cells that have receptors for histamine. The attachment of the histamine to the receptors causes the cell to be "activated," releasing other chemicals which produce the effects that we associate with allergy. Fexofenadine blocks one type of receptor for histamine (the H1 receptor) and thus prevents activation of cells by histamine. Unlike most other antihistamines, Fexofenadine does not enter the brain from the blood and, therefore, does not cause drowsiness. Fexofenadine lacks the cardiotoxic potential of terfenadine, since it does not block the potassium channel involved in repolarization of cardiac cells. Fexofenadine is sold under the trade name Allegra among others. ALLEGRA is indicated for the relief of symptoms associated with seasonal allergic
rhinitis in adults and children 2 years of age and older.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
246.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ALLEGRA Approved UseALLEGRA is indicated for the relief of symptoms associated with seasonal allergic
rhinitis in adults and children 2 years of age and older. Launch Date1996 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
523.28 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27151911 |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FEXOFENADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3507.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27151911 |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FEXOFENADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.26 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27151911 |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FEXOFENADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
690 mg 2 times / day multiple, oral Highest studied dose Dose: 690 mg, 2 times / day Route: oral Route: multiple Dose: 690 mg, 2 times / day Sources: |
healthy, 18-55 years n = 4 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 4 Sources: |
Other AEs: Headache, Tiredness... Other AEs: Headache (3 patients) Sources: Tiredness (3 patients) Dizziness (3 patients) |
800 mg single, oral Highest studied dose |
healthy, 26.9 years (range: 18-51) years n = 8 Health Status: healthy Age Group: 26.9 years (range: 18-51) years Sex: M Population Size: 8 Sources: |
Other AEs: Headache, Tiredness... Other AEs: Headache (3 patients) Sources: Tiredness (3 patients) Dizziness (3 patients) |
60 mg 2 times / day multiple, oral Highest studied dose Dose: 60 mg, 2 times / day Route: oral Route: multiple Dose: 60 mg, 2 times / day Sources: |
unhealthy, 6-11 years Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 6-11 years Sex: M+F Sources: |
|
180 mg 1 times / day multiple, oral Dose: 180 mg, 1 times / day Route: oral Route: multiple Dose: 180 mg, 1 times / day Sources: |
unhealthy, 69 years n = 1 Health Status: unhealthy Age Group: 69 years Sex: M Population Size: 1 Sources: |
Disc. AE: Papular urticarial eruption... AEs leading to discontinuation/dose reduction: Papular urticarial eruption (1 patient) Sources: |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p. 22 |
unhealthy Health Status: unhealthy Sources: Page: p. 22 |
Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache (2 patients) Sources: Page: p. 22 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dizziness | 3 patients | 690 mg 2 times / day multiple, oral Highest studied dose Dose: 690 mg, 2 times / day Route: oral Route: multiple Dose: 690 mg, 2 times / day Sources: |
healthy, 18-55 years n = 4 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 4 Sources: |
Headache | 3 patients | 690 mg 2 times / day multiple, oral Highest studied dose Dose: 690 mg, 2 times / day Route: oral Route: multiple Dose: 690 mg, 2 times / day Sources: |
healthy, 18-55 years n = 4 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 4 Sources: |
Tiredness | 3 patients | 690 mg 2 times / day multiple, oral Highest studied dose Dose: 690 mg, 2 times / day Route: oral Route: multiple Dose: 690 mg, 2 times / day Sources: |
healthy, 18-55 years n = 4 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 4 Sources: |
Dizziness | 3 patients | 800 mg single, oral Highest studied dose |
healthy, 26.9 years (range: 18-51) years n = 8 Health Status: healthy Age Group: 26.9 years (range: 18-51) years Sex: M Population Size: 8 Sources: |
Headache | 3 patients | 800 mg single, oral Highest studied dose |
healthy, 26.9 years (range: 18-51) years n = 8 Health Status: healthy Age Group: 26.9 years (range: 18-51) years Sex: M Population Size: 8 Sources: |
Tiredness | 3 patients | 800 mg single, oral Highest studied dose |
healthy, 26.9 years (range: 18-51) years n = 8 Health Status: healthy Age Group: 26.9 years (range: 18-51) years Sex: M Population Size: 8 Sources: |
Papular urticarial eruption | 1 patient Disc. AE |
180 mg 1 times / day multiple, oral Dose: 180 mg, 1 times / day Route: oral Route: multiple Dose: 180 mg, 1 times / day Sources: |
unhealthy, 69 years n = 1 Health Status: unhealthy Age Group: 69 years Sex: M Population Size: 1 Sources: |
Headache | 2 patients Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p. 22 |
unhealthy Health Status: unhealthy Sources: Page: p. 22 |
PubMed
Title | Date | PubMed |
---|---|---|
The use of antihistamines in safety-critical jobs: a meeting report. | 2002 |
|
Urticaria to cetirizine. | 2002 |
|
Liquid chromatography/tandem mass spectrometric bioanalysis using normal-phase columns with aqueous/organic mobile phases - a novel approach of eliminating evaporation and reconstitution steps in 96-well SPE. | 2002 |
|
H1-antihistamines in children. | 2002 |
|
Potential cardiac toxicity of H1-antihistamines. | 2002 |
|
Photosensitivity disorders: cause, effect and management. | 2002 |
|
[Comparative antihistamine and anti-allergic effects of various antihistamine preparations]. | 2002 |
|
[Chronic idiopathic urticaria: effectiveness of fexofenadine. A double-blind, placebo controlled study with 21 patients]. | 2002 Apr 10 |
|
[Hay fever and asthma. Many of your patients have both]. | 2002 Apr 25 |
|
Sea transport of animal and vegetable oils and its environmental consequences. | 2002 Dec |
|
Effect of fexofenadine, a mast cell blocker, in infertile men with significantly increased testicular mast cells. | 2002 Dec |
|
Effects of fexofenadine on the early response to nasal allergen challenge. | 2002 Dec |
|
Facial swelling and eosinophilia in a 44-year-old woman. | 2002 Dec |
|
Inhibitory effects of oral prednisolone and fexofenadine on skin responses by prick tests with histamine and compound 48/80. | 2002 Dec |
|
Comparative pharmacology of H1 antihistamines: clinical relevance. | 2002 Dec 16 |
|
Role of histamine in the pathophysiology of asthma: immunomodulatory and anti-inflammatory activities of H1-receptor antagonists. | 2002 Dec 16 |
|
Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. | 2002 Dec 20 |
|
An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. | 2002 Jan |
|
A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. | 2002 Jan |
|
In vivo anti-inflammatory effects of fexofenadine in chronic idiopathic urticaria. | 2002 Jul |
|
Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. | 2002 Jul |
|
Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. | 2002 Jul |
|
Role of lung inflammatory mediators as a cause of exercise-induced arterial hypoxemia in young athletes. | 2002 Jul |
|
Chronic urticaria and angioedema. | 2002 Jul 18 |
|
Simultaneous determination of fexofenadine and its related compounds by HPLC. | 2002 Jul 20 |
|
The Rx-to-OTC switch of Claritin, Allegra, and Zyrtec: an unprecedented FDA response to petitioners and the protection of public health. | 2002 Jun |
|
Effect of St John's wort on the pharmacokinetics of fexofenadine. | 2002 Jun |
|
Are herbal products dietary supplements or drugs? An important question for public safety. | 2002 Jun |
|
Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block. | 2002 Jun 18 |
|
Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines. | 2002 May |
|
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. | 2002 May |
|
Transport of the sulfated, amidated bile acid, sulfolithocholyltaurine, into rat hepatocytes is mediated by Oatp1 and Oatp2. | 2002 May |
|
Clinical pharmacology of H1-antihistamines in the skin. | 2002 Nov |
|
Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. | 2002 Nov |
|
The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia. | 2002 Nov |
|
The use of handheld computers in clinical trials. | 2002 Oct |
|
Review of fexofenadine in the treatment of chronic idiopathic urticaria. | 2002 Oct |
|
Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. | 2002 Oct |
|
Determination of some histamine H1-receptor antagonists in dosage forms. | 2002 Oct 15 |
|
Chronic urticaria: a role for newer immunomodulatory drugs? | 2003 |
|
The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers. | 2003 Apr |
|
Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis. | 2003 Apr |
|
Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis. | 2003 Apr |
|
The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel. | 2003 Feb |
|
Effect of fexofenadine hydrochloride on cedar pollinosis. | 2003 Feb |
|
Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. | 2003 Jan |
|
Why aren't lower, effective, OTC doses available earlier by prescription? | 2003 Jan |
|
Solar urticaria induced by infrared radiation. | 2003 Mar |
|
Decongestant effects of antihistamines: a class effect? | 2003 Mar |
|
Spectrophotometric determination of binary mixtures of pseudoephedrine with some histamine H1-receptor antagonists using derivative ratio spectrum method. | 2003 Mar 26 |
Sample Use Guides
Seasonal Allergic Rhinitis and Chronic Idiopathic Urticaria
Adults and Children 12 Years and Older: The recommended dose of ALLEGRA (Fexofenadine)
tablets is 60 mg twice daily or 180 mg once daily with water. A dose of 60 mg once daily is
recommended as the starting dose in patients with decreased renal function
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24260772
The addition of fexofenadine at a dose of 10E-4 M elicited a significant relaxation response in isolated rat tracheas.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000000190
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
||
|
WHO-ATC |
R06AX26
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
||
|
NDF-RT |
N0000175587
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
||
|
WHO-VATC |
QR06AX26
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
||
|
LIVERTOX |
NBK548571
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1170
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
83799-24-0
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
Fexofenadine
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
C093230
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
CHEMBL914
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
7486
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
FEXOFENADINE
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
4819
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
87636
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | RxNorm | ||
|
3348
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
E6582LOH6V
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
m5367
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | Merck Index | ||
|
1270363
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
SUB13883MIG
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
C61764
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
DTXSID00861411
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
100000078495
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
5050
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
DB00950
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
7469
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY | |||
|
E6582LOH6V
Created by
admin on Sat Dec 16 16:12:53 GMT 2023 , Edited by admin on Sat Dec 16 16:12:53 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)